Diana De Ronchi

2 papers in the library · 48 citations · publishing 2023-2024

Papers

Clinical specificity profile for novel rapid acting antidepressant drugs.

International clinical psychopharmacology September 1, 2023 Mauro Scala, Giuseppe Fanelli, Diana De Ronchi et al. 40 citations

Mood disorders are long-lasting conditions with inconsistent remission rates. Standard antidepressants fail many patients, cause side effects like weight gain and sexual problems, and act slowly. Newer drugs aim to work faster, with fewer side effects, and target symptoms poorly addressed by older medications, such as anhedonia, suicidal thoughts, insomnia, cognitive deficits, and irritability. These agents act on glutamate, GABA, orexin, and other receptors, offering more pharmacodynamic variety to personalize treatment. This review covers the clinical profiles of nine novel compounds—including psilocybin, esmethadone, and zuranolone—to help clinicians weigh benefits and risks for patients with different mood disorder symptoms and comorbidities.

DOI: 10.1097/yic.0000000000000488 Full text Antidepressants Mental health treatment Neuroscience Psychiatric medicine +1

The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.

CNS spectrums December 1, 2024 Mauro Scala, Chiara Fabbri, Paolo Fusar-Poli et al. 8 citations

Psilocybin shows promise for treating mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder, but significant evidence gaps remain. Current studies suggest psilocybin may alleviate depression, anxiety, obsessions, compulsions, and addictive behaviors, yet comparisons with standard antidepressants or anxiolytics are lacking, and optimal dosage, long-term efficacy, and safety are unclear due to trial limitations. Real-world implementation faces challenges including infrastructural requirements, personnel training, cultural stigma, and unresolved legal and ethical issues. Larger, more rigorous studies are needed to substantiate the evidence base before psilocybin can transition from research to clinical practice.

DOI: 10.1017/s1092852924002268 Full text Psilocybin Addiction Psilocin Synaptic plasticity +11